Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms GIMEMA; OPUS
- 14 Sep 2016 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 14 Sep 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.